Krystal Biotech (NASDAQ:KRYS) Posts Quarterly Earnings Results, Misses Estimates By $0.17 EPS

Krystal Biotech (NASDAQ:KRYS) issued its quarterly earnings data on Monday. The company reported $0.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.20 by ($0.17), Briefing.com reports. The firm had revenue of $45.25 million for the quarter, compared to the consensus estimate of $47.37 million. The firm’s quarterly revenue was up 452400.0% compared to the same quarter last year. During the same period last year, the company earned ($1.76) earnings per share.

Krystal Biotech Stock Performance

NASDAQ:KRYS traded up $0.69 during mid-day trading on Thursday, hitting $158.37. 4,889 shares of the stock were exchanged, compared to its average volume of 359,831. Krystal Biotech has a fifty-two week low of $86.03 and a fifty-two week high of $189.97. The stock has a market capitalization of $4.52 billion, a price-to-earnings ratio of 1,971.25 and a beta of 0.91. The firm’s 50-day simple moving average is $168.76 and its 200 day simple moving average is $134.27.

Insider Transactions at Krystal Biotech

In related news, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $170.96, for a total transaction of $4,274,000.00. Following the transaction, the insider now directly owns 1,550,882 shares of the company’s stock, valued at $265,138,786.72. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In related news, CAO Kathryn Romano sold 8,087 shares of the firm’s stock in a transaction on Monday, February 26th. The stock was sold at an average price of $136.91, for a total value of $1,107,191.17. Following the transaction, the chief accounting officer now owns 12,556 shares in the company, valued at $1,719,041.96. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $170.96, for a total value of $4,274,000.00. Following the completion of the transaction, the insider now directly owns 1,550,882 shares of the company’s stock, valued at approximately $265,138,786.72. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 38,087 shares of company stock valued at $6,210,591. 14.10% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the stock. Stifel Nicolaus reissued a “buy” rating and set a $204.00 price target (up from $178.00) on shares of Krystal Biotech in a research report on Tuesday, April 16th. William Blair reaffirmed an “outperform” rating on shares of Krystal Biotech in a research report on Tuesday, February 27th. HC Wainwright reissued a “buy” rating and issued a $200.00 price objective on shares of Krystal Biotech in a report on Monday. Guggenheim boosted their target price on shares of Krystal Biotech from $130.00 to $175.00 and gave the stock a “buy” rating in a report on Tuesday, February 27th. Finally, Citigroup increased their price target on shares of Krystal Biotech from $160.00 to $195.00 and gave the company a “buy” rating in a research note on Tuesday, February 27th. Nine equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Krystal Biotech has an average rating of “Buy” and an average price target of $171.00.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).